Identification of arylsulfonamides as Aquaporin 4 inhibitors

https://doi.org/10.1016/j.bmcl.2006.12.010Get rights and content

Abstract

Carbonic anhydrase inhibitors AZA, EZA, and 4-acetamidobenzsulfonamide were found to inhibit human AQP4-M23 mediated water transport by 80%, 68%, and 23%, respectively, at 20 μM in an in vitro functional assay. AZA was found to have an IC50 against AQP4 of 0.9 μM. Phloretin was inactive under the same conditions.

Graphical abstract

A series of carbonic anhydrase inhibitors, including AZA, have been found to inhibit AQP4 mediated water transport in an in vitro functional assay. AZA has an apparent IC50 = 0.9 μM against human AQP4-M23.

  1. Download : Download full-size image

Section snippets

Acknowledgments

Support for this research was provided from the Ministry of Education, Culture, Sports, Science and Technology (Japan); Grant for the Promotion of University of Niigata Research Projects (University of Niigata, Center for Transdisciplinary Research); Takeda Science Foundation.

References and notes (31)

  • H. Hasegawa et al.

    J. Biol. Chem.

    (1994)
  • N.A. Castle

    DDT

    (2005)
  • F.J.M. Detmers et al.

    J. Biol. Chem.

    (2006)
  • J. Gao et al.

    Anal. Biochem.

    (2006)
  • D.-S. Koh et al.

    Neurosci. Lett.

    (1994)
  • B. Yang et al.

    J. Biol. Chem.

    (2001)
  • Y. Hiroaki et al.

    J. Mol. Biol.

    (2006)
  • K. Sakimura et al.

    FEBS Lett.

    (1990)
  • Ö. Özensoy et al.

    Bioorg. Med. Chem. Lett.

    (2005)
  • P. Agre

    Proc. Am. Thor. Soc.

    (2006)
  • E. Kruse et al.

    Gen. Bio.

    (2006)
  • J.S. Jung et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (1994)
  • G.T. Manley et al.

    Neuroscience

    (2004)
  • D.K. Binder et al.

    Neuroreport

    (2004)
  • T. Eid et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (2005)
  • Cited by (121)

    • Recent breakthroughs and future directions in drugging aquaporins

      2022, Trends in Pharmacological Sciences
      Citation Excerpt :

      N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl) acetamide is a derivative of acetazolamide that is active against carbonic anhydrase (IC50 72 nM), and a candidate AQP4 inhibitor [33]. Ethoxyzolamide, another carbonic anhydrase inhibitor, was reported to inhibit human AQP4-M23-mediated water transport when tested at 20 μM [31] in oocytes. Other studies have described acetazolamide inhibition of aquaporin-mediated water transport due to the downregulation of expression, rather than a direct inhibition of channel function [34].

    • Aquaporins in lung health and disease: Emerging roles, regulation, and clinical implications

      2020, Respiratory Medicine
      Citation Excerpt :

      Consequently, there is a need to focus on their active components to design synthetic analogs as small molecule therapeutics or generate recombinant macromolecule (protein) therapeutics. Initial efforts toward discovery of small-molecule therapeutic agents for aquaporins indicated the potential of aryl sulfonamides and antiepileptics [182–184]. However, further efficacy studies failed to confirm the translational value of these agents [185].

    • Toward New AQP4 Inhibitors: ORI-TRN-002

      2024, International Journal of Molecular Sciences
    View all citing articles on Scopus
    View full text